Finanzen von 111 Inc (YI)YI111 Inc

111 Inc (YI) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Product Revenues, accounting for 99.1% of total sales, equivalent to CNY 3.39B. Another important revenue stream is Service Revenues. Understanding this composition is critical for investors evaluating how YI navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, 111 Inc maintains a gross margin of 5.75%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1.01%, while the net margin is -1.38%. These profitability ratios, combined with a Return on Equity (ROE) of -54.87%, provide a clear picture of how effectively YI converts its operational activities into shareholder value.

In the context of the broader market, YI competes directly with industry leaders such as MYO and JWEL. With a market capitalization of $25.52M, it holds a significant position in the sector. When comparing efficiency, YI's gross margin of 5.75% stands against MYO's 72.13% and JWEL's 8.16%. Such benchmarking helps identify whether 111 Inc is trading at a premium or discount relative to its financial performance.

111 Inc has been struggling financially, with a net income of -$37.04 million in Q1 2026 and a gross margin of only 5.33%. The company has seen a consistent decline in revenue, with a 33.1% drop year-over-year in Q1 2026, reflecting ongoing operational challenges.